Core Viewpoint - Guardian Pharmacy Services Inc. has shown strong financial performance and has received positive ratings from analysts, indicating a favorable outlook for the company in the long-term care pharmacy services sector [1][5]. Financial Performance - The company reported quarterly earnings of $0.37 per share, exceeding the Zacks Consensus Estimate of $0.27, representing a 54.81% increase from $0.24 per share in the same quarter last year [2]. - Revenues for the quarter ending December 2025 reached $397.62 million, surpassing the Zacks Consensus Estimate by 2.41%, and marking a significant increase from $338.57 million in the same period the previous year [3]. - The net income for the fourth quarter surged by 81% to $21.3 million, compared to $11.8 million in the same period the previous year, while adjusted EBITDA increased by 53% to $39.5 million [4]. - For the full year 2025, Guardian Pharmacy Services reported revenue of $1.45 billion, reflecting an 18% increase from the previous year [4]. Analyst Ratings - Raymond James upgraded Guardian Pharmacy Services to "Outperform" with a price target increase to $40, while the stock was priced at $33.27 at the time of the update [1]. - The company has been assigned a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings prospects driven by an upward trend in earnings estimates [5].